NAD+ depletion radiosensitizes 2-DG-treated glioma cells by abolishing metabolic adaptation

Free Radic Biol Med. 2021 Jan:162:514-522. doi: 10.1016/j.freeradbiomed.2020.11.007. Epub 2020 Nov 13.

Abstract

Two-deoxy-d-glucose (2-DG) mediated glucose restriction (GR) has been applied as a potential therapeutic strategy for tumor clinical treatments. However, increasing evidences have indicated that 2-DG alone is inefficient in killing tumor cells, and the effect of 2-DG on modifying tumor radio-responses also remains controversial. In this study, we found that 2-DG triggered metabolic adaption in U87 glioma cells by up-regulating nicotinamide phosphoribosyltransferase (NAMPT) and cellular NAD+ content, which abolished 2-DG-induced potential radiosensitizing effect in glioma cells. Strikingly, NAD+ depletion evoked notable oxidative stress by NADPH reduction and hence re-radiosensitized 2-DG-treated glioma cells. Furthermore, isocitrate dehydrogenase-1 (IDH1) mutant U87 glioma cells with deficiency in the rate-limiting enzyme of Preiss-Handler pathway nicotinate phosphoribosyltransferase (Naprt1) revealed notable 2-DG-induced oxidative stress and radiosensitization. Our findings implied that targeting NAD+ could radiosensitize gliomas with GR, and 2-DG administration could be benefit for tumor patients with IDH1 mutation.

Keywords: Glucose restriction; IDH1 mutation; NAD+; NAMPT; Radiosensitivity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Glioma* / drug therapy
  • Glioma* / genetics
  • Glioma* / radiotherapy
  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Mutation
  • NAD*
  • NADP

Substances

  • NAD
  • NADP
  • Isocitrate Dehydrogenase